SEC Form 4 · accession 0001144204-18-050965
TITAN PHARMACEUTICALS INC · TTNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Federico Seghi Recli
Director
Period of report
Sep 24, 2018
Accepted (ET)
Sep 26, 2018 · 5:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000910267
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 24, 2018 | P$0 | 500,000 | — | A | 600,845 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The weighted average price is $0.2276 per share while the low trade price is at $0.2223 and the high trade price at $0.235.